Login Register Cart 0
Generic placeholder image

Letters in Organic Chemistry

Editor-in-Chief

ISSN (Print): 1570-1786
ISSN (Online): 1875-6255

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis and Biological Potentials of 5-aryl-N-[4-(trifluoromethyl) phenyl]-1,3,4-oxadiazol-2-amines

Author(s): Mohamed Jawed Ahsan*, Mohd. Zaheen Hassan, Surender Singh Jadav, Mohammed H. Geesi, Mohammed Afroz Bakht, Yassine Riadi, Salahuddin, Md. Sayeed Akhtar, Mohammad Nasar Mallick and Md. Habban Akhter

Volume 17, Issue 2, 2020

Page: [133 - 140] Pages: 8

DOI: 10.2174/1570178616666190401193928

Price: $65

Abstract

Oxadiazoles are an important class of heterocyclic compounds, having broad-spectrum activity. They were also reported as anticancer, and antioxidant agents, hence it is of significant importance to explore new oxadiazoles. A series of eleven (5-aryl-N-[4-(trifluoromethyl)phenyl]-1,3,4- oxadiazol-2-amines (6a-k) was synthesized based on the structures of reported compounds, SU-101, IMC38525, and FTAB. All these oxadiazoles were synthesized, characterized by spectral data, and further tested against melanoma, leukemia, colon, lung, CNS, ovarian, renal, breast and prostate cancer cell lines’ panels at a single dose of 10 μM drug concentrations. N-(4-(Trifluoromethyl)phenyl)-5-(3,4- dimethoxyphenyl)-1,3,4-oxadiazol-2-amine (6h) showed significant anticancer activity, and the most sensitive five cell lines were NCI-H522 (% GI = 53.24), K-562 (% GI = 47.22), MOLT-4 (% GI = 43.87), LOX-IMVI (% GI = 43.62), and HL-60(TB) (% GI = 40.30). The compound, 6h revealed better %GIs than imatinib, against 36 cell lines, taking 54 cell lines in common. The maximum sensitivity was recorded against cancer cell line CCRF-CEM (% GI = 68.89) by 2-(5-(4-(trifluoromethyl) phenylamino)-1,3,4-oxadiazol-2-yl)phenol (6f). The antioxidant activity of 4-(5-(4-(trifluoromethyl) phenylamino)-1,3,4-oxadiazol-2-yl)-2-methoxyphenol (6i) was promising with an IC50 of 15.14 μM. It was observed that the oxadiazoles reported herein showed significant anticancer and antioxidant activities.

Keywords: Anticancer, antioxidants, DPPH assay, oxadiazoles, one dose assay, heterocyclic compounds.

« Previous Next »
Graphical Abstract

[1]
Facts & Figures 2018: Rate of Deaths From Cancer Continues Decline Retrieved from:. https://www.cancer.org/latest-news/facts-and-figures-2018-rate-of-deaths-from-cancer-continues-decline.html (February 29th 2018).
[2]
Siegel, R.L.; Miller, D.K.; Jemal, A. CA Cancer J. Clin., 2018, 68, 7-30.
[3]
WHO Cancer Statistics: Retrieved from. http://www.who.int/ mediacentre/factsheets/fs297/en/ (February 29th 2018)
[4]
Aydemir, N.; Bilaloglu, R. Mutat. Res., 2003, 537, 43-51.
[5]
Birben, E.; Sahiner, U.M.; Sackesen, C.; Erzurum, S.; Kalayci, O. World Allergy Organ. J., 2012, 5, 9-19.
[6]
Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Free Radic. Biol. Med., 2010, 49(11), 1603-1616.
[7]
Pham-Huy, L.A.; He, H.; Pham-Huy, C. Int. J. Biomed. Sci., 2008, 4, 89-96.
[8]
Vaidya, A.; Jain, S.; Jain, P.; Jain, P.; Tiwari, N.; Jain, R.; Jain, R.; Jain, A.K.; Agrawal, R.K. Mini Rev. Med. Chem., 2016, 16, 825-845.
[9]
Zhang, K.; Wang, P.; Xuan, L.; Fu, X.; Jing, F.; Li, S.; Liu, Y.; Chen, B. Bioorg. Med. Chem. Lett., 2014, 24, 5154-5156.
[10]
Ahsan, M.J.; Samy, G.J.; Habibullah, K.; Nomani, M.S.; Saraswat, P.; Gaur, R.; Singh, A. Bioorg. Med. Chem. Lett., 2011, 21, 7246-7250.
[11]
Rathore, A.; Sudhakar, R.; Ahsan, M.J.; Ali, A.; Subbarao, N.; Jadav, S.S.; Umar, S. ShaharYar, M. Bioorg. Chem., 2017, 70, 107-117.
[12]
Bakht, M.A.; Yar, M.S.; Abdel-Hamid, S.G.; Al-Qasoumi, S.I.; Samad, A. Eur. J. Med. Chem., 2010, 45, 5862-5869.
[13]
Tabatabai, S.A.; Lashkari, S.B.; Zarrindast, M.R.; Golibeikian, M.; Shafiee, A. Iranian J. Pharm. Sci., 2013, 12S, 105-111.
[14]
Khan, M.U.; Akhtar, T.; Al-Masoudi, N.A.; Stoeckli-Evans, H.; Hameed, S. Med. Chem., 2012, 8, 1190-1197.
[15]
Kamal, A.; Srikanth, P.S.; Vishnuvardhan, M.V.P.S.; Kumar, G.B.; Babu, K.S.; Hussaini, S.M.A.; Kapure, J.S.; Alarifi, A. Bioorg. Chem., 2016, 65, 126-136.
[16]
Tuma, C.M.; Malikzay, A.; Ouyang, X.; Surguladze, D.; Fleming, J.; Mitelman, S.; Camara, M.; Finnerty, B.; Doody, J.; Chekler, E.L.P.; Kussie, P.; Tonra, J.R. Transl. Oncol., 2010, 3, 318-325.
[17]
Ahsan, M.J.; Choupra, A.; Sharma, R.K.; Jadav, S.S.; Hassan, M.Z.; Bakht, M.A.; Padmaja, P.; Al-Tamini, A.B.S.; Geesi, M.H. Anticancer. Agents Med. Chem., 2018, 18, 121-138.
[18]
Bohm, H.J.; Flohr, A.; Stahl, M. Scaffold hoping. Drug Discov. Today. Technol., 2004, 1, 217-224.
[19]
Agarwal, M.; Singh, V.; Sharma, S.K.; Sharma, P.; Ansari, M.Y.; Jadav, S.S.; Yasmin, S.; Sreenivasulu, R.; Hassan, M.Z.; Saini, V.; Ahsan, M.J. Med. Chem. Res., 2016, 25, 2289-2303.
[20]
Ahsan, M.J. ChemistrySelect, 2016, 1, 4713-4720.
[21]
Ahsan, M.J.; Meena, R.; Dubey, S.; Khan, V.; Manda, S.; Jadav, S.S.; Sharma, P. Geesi, M.H.; Hassan, M.Z.; Bakht, M.A.; Riadi, Y.; Akhter, M.H.; Salahuddin.; Gundla, R. Med. Chem. Res., 2018, 27, 864-883.
[22]
Ahsan, M.J.; Sharma, J.; Singh, M.; Jadav, S.S.; Yasmin, S. Bio- Med Res Int; , 2014. Article ID: 814984, 9 pages..
[23]
Rzeski, W.; Matysiak, J.; Kandefer-Szerszen, M. Bioorg. Med. Chem., 2007, 15, 3201-3207.
[24]
Juszczak, M.; Matysiak, J.; Szeliga, M.; Pozarowski, P.; Niewiadomy, A.; Albrecht, J.; Rzeski, W. Bioorg. Med. Chem. Lett., 2012, 22, 5466-5469.
[25]
Garber, K. J. Natl. Cancer Inst., 2000, 92, 967-969.
[26]
Nitti, A.; Signorile, M.; Boiocchi, M.; Bianchi, G.; Po, R.; Pasini, D. J. Org. Chem., 2016, 81, 11035-11042.
[27]
Nitti, A.; Bianchi, G.; Po, R.; Swager, T.M.; Pasini, D. J. Am. Chem. Soc., 2017, 139, 8788-8791.
[28]
Pasini, D.; Takeuchi, D. Chem. Rev., 2018, 118, 8983-9057.
[29]
Colombo, S.; Coluccini, C.; Caricato, M.; Gargiulli, C.; Gattuso, G.; Pasini, D. Tetrahedron, 2010, 66, 4206-4211.
[30]
Yogeeswari, P.; Sriram, D.; Thirumurugan, R.; Saxena, A.; Stables, J.; Vaigunda, J. Raghuvendran, Suddan, K.; Pavana, R.K. J. Med. Chem., 2005, 48, 6202-6211.
[31]
Amir, M.; Ahsan, M.J.; Ali, I. Indian J. Chem., 2010, 49B, 1509-1515.
[32]
Polkam, N.; Kummari, B.; Rayam, P.; Brahma, U.; Naidu, V.G.M.; Balasubramanian, S.; Anireddy, J.S. ChemistrySelect, 2017, 2, 5492-5496.
[33]
Development therapeutic program NCI/NIH (2014.). http://dtp.nci.nih.gov (Accessed 13 November 2014).
[34]
Boyd, M.R.; Paull, K.D. Drug Dev. Res., 1995, 34, 91-109.
[35]
Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. J. Natl. Cancer Inst., 1991, 83, 757-766.
[36]
Shoemaker, R.H. Nat. Rev. Cancer, 2006, 6, 813-823.
[37]
NCI database compound ID NSC 759854 (Imatinib). NSC 757384 (Vin blastin sulfate) Retrieved from. https://dtp.cancer.gov
[38]
Koleva, I.I.; Van-Beek, T.A.; Linssen, J.P.; de-Groot, A.; Evstatieva, L.N. Phytochem. Anal., 2002, 13, 8-17.

Rights & Permissions Print Cite
Article Metrics
20
© 2024 Bentham Science Publishers | Privacy Policy